Abstract
Introduction In March 2020, Qatar started reporting increased numbers of COVID-19 positive cases. The Ministry of Public Health in Qatar has developed an emergency action plan to respond to the outbreak with the Primary Health Care Corporation (PHCC) as a main component of that response.
Aim The aim of this review is to understand and document the Impact of COVID 19 on PHCC in Qatar in terms of response, modifications of services and introduction of new alternatives
Methodology A retrospective data analysis was conducted for all the COVID-19 swabbing activities and for all the utilization services volume across the PHCC health centers between January 2018 and May 2020.
Results PHCC allocated testing sites for COVID-19 resulted in conducting 54824 swabs with 11455 positive cases and positivity rate of 20.8% between 14th of March and 15th of June 2020. The overall PHCC services utilization declined with overall reduction of 50% in April 2020. Alternative virtual and remote services were provided, telemedicine was introduced, and it made up 50% of the consultation volumes for April 2020. Home refill delivery medications managed to provide a total of 20920 delivered prescriptions by end of May 2020.
Conclusion and recommendations To decrease the risk of infection to the patients and health care workers, PHCC in Qatar cancelled the appointments for some high-risk population. However, PHCC introduced virtual remote services that managed to make up for the in-person utilization volume and reflected acceptance in patients’ behaviours. PHCC continued in detecting positive COVID-19 cases among its targeted communities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
N/A
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data presented in this research was volume utilization data, no patients level data was accessed.Hence, the research was exempted from the IRB approval
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The volume data for the services utilization are available upon request
